[ad_1]
AlphaStreet Newsdesk powered by AlphaStreet Intelligence
ANRO|EPS -$0.80|Net Loss $26.2MAlto Neuroscience Inc reported a wider quarterly loss for the first three months of 2026, reflecting increased spending as the precision psychiatry company advances its clinical pipeline. The biotech firm posted a basic and diluted loss per share of $0.80 for Q1 2026, widening 42.9% from the $0.56 loss recorded in the same period last year.
The bottom line showed a net loss of $26.2M for the quarter. Alto Neuroscience, which trades on the New York Stock Exchange under the ticker ANRO, has been building its platform that aims to match patients with targeted psychiatric treatments based on brain biomarkers rather than trial-and-error prescribing.
The company operates in a sector where high research and development costs typically generate losses during clinical development phases. Wall Street maintains a largely positive outlook on the stock despite the widening losses, with analyst consensus standing at 7 buy ratings, 2 hold ratings, and 0 sell ratings. The neuroscience-focused biotech has been working to differentiate itself in the competitive mental health therapeutics space through its data-driven approach to drug development and patient selection.
This content is for informational purposes only and should not be considered investment advice. AlphaStreet Intelligence analyzes financial data using AI to deliver fast and accurate market information. Human editors verify content.
[ad_2]
Source link